Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 5/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL5550497 | 0.97 | CYP3A4 (0.40) | CYP3A4ADRB2ADRB1ADRB3ALDH1A1 | |
| Phosphine SCHEMBL3822065 | 0.97 | CYP3A4 (0.46) | CYP3A4ADRB2ADRB1ADRB3ALDH1A1 | |
| Water SCHEMBL11127184 | 0.97 | CYP3A4 (0.40) | CYP3A4ADRB2ADRB1ADRB3ALDH1A1 | |
| SCHEMBL324579 | 0.92 | CA1 (0.41) | ALDH1A1CA1CA2TSHRHPGD | |
| SCHEMBL3639078 | 0.90 | TSHR (0.46) | CYP3A4ADRB2ADRB1ADRB3ALDH1A1 | |
| SCHEMBL9542977 | 0.89 | CA1 (0.43) | ALDH1A1CA1CA2TSHRHPGD | |
| SCHEMBL326032 | 0.89 | CA1 (0.43) | ALDH1A1CA1CA2TSHRHPGD | |
| SCHEMBL273331 | 0.89 | CA1 (0.43) | ALDH1A1CA1CA2TSHRHPGD | |
| SCHEMBL324701 | 0.89 | CA1 (0.43) | ALDH1A1CA1CA2TSHRHPGD | |
| SCHEMBL11232265 | 0.89 | CA1 (0.43) | ALDH1A1CA1CA2TSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590249-B2 | Etchant composition | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2026-03-31 | — | — | US | claimed |
| CN-114678591-B | Lithium-sulfur battery electrolyte, lithium-sulfur battery and activation method thereof | 清华大学 | 2025-05-30 | — | — | CN | claimed |
| CN-119931727-A | Fuel composition and application thereof | 中国石油化工股份有限公司 | 2025-05-06 | — | — | CN | claimed |
| CN-117756186-B | Preparation method of shape-controllable doped carbon-coated molybdate-based ferric oxide flower-shaped composite material | 齐齐哈尔大学 | 2025-04-04 | — | — | CN | claimed |
| CN-119613980-A | High-temperature high-pressure filtrate reducer sulfonated asphalt for drilling fluid and preparation method thereof | 河南省新乡市第七化工有限公司 | 2025-03-14 | — | — | CN | claimed |
| CN-115810798-A | Electrolyte solution, secondary battery, battery module, battery pack, and electric device | 宁德时代新能源科技股份有限公司 | 2023-03-17 | — | — | CN | claimed |
| CN-115093301-B | Fluorine-containing adhesive system poured metallized explosive and preparation method thereof | 北京理工大学 | 2023-02-10 | — | — | CN | claimed |
| CN-115558532-A | Environment-friendly fuel for engine | 姚焱 | 2023-01-03 | — | — | CN | claimed |
| US-20220406428-A1 | METHODS FOR TREATING ERECTILE DYSFUNCTION WITH A CGMP-SPECIFIC PHOSPHODIESTERASE 5 INHIBITOR PHARMACEUTICAL COMPOSITION | ASTRAZENECA UK LIMITED (GB) | 2022-12-22 | — | — | US | claimed |
| CN-115093301-A | Fluorine-containing adhesive system poured metallized explosive and preparation method thereof | 北京理工大学 | 2022-09-23 | — | — | CN | claimed |
| EP-0740528-A4 | GAS MICROSPHERES FOR TOPICAL AND SUBCUTANEOUS APPLICATION | IMARX PHARMACEUTICAL CORP (US) | 1998-04-01 | — | — | EP | claimed |
| US-5733572-A | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles | IMARX PHARMACEUTICAL CORP. (US) | 1998-03-31 | — | — | US | claimed |
| EP-0802788-A1 | NOVEL THERAPEUTIC DELIVERY SYSTEMS | UNGER, Evan C (US) | 1997-10-29 | — | — | EP | claimed |
| EP-0740528-A1 | GAS MICROSPHERES FOR TOPICAL AND SUBCUTANEOUS APPLICATION | IMARX PHARMACEUTICAL CORP. (US) | 1996-11-06 | — | — | EP | claimed |
| EP-0712293-A1 | METHODS OF PREPARING GAS AND GASEOUS PRECURSOR-FILLED MICROSPHERES | UNGER, Evan C (US) | 1996-05-22 | — | — | EP | claimed |
| US-5482518-A | FUEL ADDITIVES | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1996-01-09 | — | — | US | claimed |
| WO-1995015118-A1 | GAS MICROSPHERES FOR TOPICAL AND SUBCUTANEOUS APPLICATION | IMARX PHARMACEUTICAL CORP. (US) | 1995-06-08 | — | — | WO | claimed |
| WO-1994028780-A2 | METHODS OF PREPARING GAS AND GASEOUS PRECURSOR-FILLED MICROSPHERES | UNGER EVAN C (US) | 1994-12-22 | — | — | WO | claimed |
| WO-1994028874-A1 | NOVEL THERAPEUTIC DELIVERY SYSTEMS | UNGER EVAN C (US) | 1994-12-22 | — | — | WO | claimed |
| US-4365973-A | Middle distillate fuel additive | UNION OIL COMPANY OF CALIFORNIA (US) | 1982-12-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220406428-A1 | METHODS FOR TREATING ERECTILE DYSFUNCTION WITH A CGMP-SPECIFIC PHOSPHODIESTERASE 5 INHIBITOR PHARMACEUTICAL COMPOSITION | PDE5A, PDE3A, PDE3B | CYP3A4 813/4885ADRB2 124/4885ADRB1 88/4885 |
| US-12590249-B2 | Etchant composition | ASIC1, NOS1, CA1 | CYP3A4 4006/4885ADRB2 3729/4885ADRB1 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.